COMMUNIQUÉS West-GlobeNewswire

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time
12/06/2025
GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2025
12/06/2025
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 mai 2025
12/06/2025
Nombre total de droits de vote et d’actions composant le capital social au 31 mai 2025 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
12/06/2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Ipsen - Mai 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
12/06/2025
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
12/06/2025
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML AML patients with diverse mutations, including TP53-mutated/CK and FLT3- [...]
Bay Area Lyme Foundation Announces National Winner of the 2025 Emerging Leader Award to Develop a Much-Needed Rapid, Low-Cost, Easy-to-Use Lyme Disease Test
12/06/2025
Winner Chao Wang of Arizona State University will receive $150,000 to evaluate a unique diagnostic that uses gold nanoparticles and has been proven in other infectious diseases PORTOLA VALLEY, Calif., June 12, 2025 ( [...]
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
12/06/2025
Vancouver, Canada, June 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“ [...]
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements
12/06/2025
1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical [...]
Sharecare introduces new interactive solutions to elevate health literacy and increase condition-specific treatment adherence
12/06/2025
Utilizing augmented reality, artificial intelligence, and time-based visualization, Sharecare’s newest innovative tools help life sciences brands engage, educate, and activate patients ATLANTA, June 12, 2025 (GLOBE [...]
RadioMedix Debuts Proprietary bench top ²¹²Pb Generator to Support Targeted Alpha Therapy Development
12/06/2025
New bench top ²¹²Pb generator to expand clinical-grade isotope supply for targeted alpha therapy research and development HOUSTON, June 12, 2025 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology [...]
Fortrea Adopts Limited-Duration Stockholder Rights Plan
12/06/2025
Board Committed to Protecting Long-Term Value for All Stockholders DURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today [...]
Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative
12/06/2025
GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused [...]
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
12/06/2025
Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapies PITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc [...]
Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities
12/06/2025
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through [...]
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
12/06/2025
Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech [...]
SteraMist Named Disinfection and Decontamination Products Company of the Year 2025
12/06/2025
FREDERICK, Md., June 12, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today is proud to announce it [...]
Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon
12/06/2025
Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics) Raises full year revenue outlook to $80 - $100 million (excluding ACT Genomics) IM8 contributed $5.7 million in Q1, with $2.8 million in [...]
NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations
12/06/2025
TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transforming clinical [...]

Pages